Research Interests Study of new alterations in metabolic pathways, and of clusters and hubs in the aging nervous system and at early stages of neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), Dementia with Lewy Bodies, tauopathies, other frontotemporal lobar degenerations, prion diseases and amyotrophic lateral sclerosis; combined use of genomics, transcriptomics, proteomics, redox proteomics, metabolomics, lipidomics and bioinformatic processing followed by validation by qRT-PCR, western blotting, ELISA, immunohistochemistry and enzymatic studies; all this on human post-mortem brain samples from our brain bank and other centers belonging to the European Brain Bank Network Consortium; national and international collaborations; translation of the results to basal transgenic murine models and newly generated double-transgenic animals; use of these models to test possible treatments; and assessment of possible CSF biomarkers mainly based on metabolomes. Our main goal has been the identification of new pathways, networks, hubs and clusters which are modified with age and altered at the initial stages of common neurodegenerative diseases, in order to i. gain understanding about pathogenic factors occurring during brain involution and at early stages of neurodegenerative diseases in old age; ii. identify altered interconnected clusters, odes and hubs; and iii recognize putative targets and treatments for therapeutic prevention.